Mapatumumab (identified through the reference number 658052-09-6) represents an novel monoclonal antibody aimed at the specific domain of PRTK4. This mechanism centers on selectively blocking PRTK4 signaling, resulting in plays the essential function in cancer angiogenesis and metastasis. Consequently, this compound shows efficacy as a oncologic therapy via disrupting neoplastic vascular network and restricting its capacity to spread.
HGS-ETR1 Unveiling the Potential of MAB-008
Emerging data surrounding HGS-ETR1 – a protein involved in tumor growth and spread – underscores a promising potential for therapeutic intervention. Mapatumumab , a humanized IgG targeting HGS-ETR1 , displays encouraging benefit against pre-clinical platforms and early-phase human trials indicate limited signals of tumor-inhibiting effect .
Additional exploration aims on refining Mapatumumab's delivery and defining tumor subsets most apt to benefit from this advanced treatment .
- Animal research
- Initial clinical studies
- Targeted disease groups
Mapatumumab (HGSETR1): Clinical Trials and Therapeutic Prospects
Mapatumumab is revealing positive outcomes in future clinical trials, particularly addressing individual-sourced secreted matrix factors associated with tumor microenvironment. Phase 1.5 investigations have suggested anti-angiogenic effects and initial signs of treatment advantage in patients with refractory non-small lung bronchial tumor. Further studies are assessing its possibility in with existing approaches and exploring its usefulness across various tumor types to increase its therapeutic influence.
Understanding the Role of HGSETR1 in Disease: Focusing on Mapatumumab
Understanding a function of HGSETR1 in illness presents an area of increasing attention. Specifically , its association to inflammatory conditions highlights its possible relevance to various human situations. Matpatumumab , a monoclonal protein that binds this factor, offers a novel approach for assessing its action and conceivably treating associated diseases .
658052-09-6: The Chemical Profile of Mapatumumab and its Significance
The compound identified by the CAS registry number 658052-09-6 represents Mapatumumab, a chimeric protein targeting glycoprotein target CSF1R. Its structural formula is CnumberHnumberNnumberOnumberSnumber, reflecting a large polypeptide structure with a molecular weight of approximately value grams per mole. This investigational agent demonstrates significant binding to CSF1R, influencing macrophage function and exhibiting promise in treating certain conditions . Further investigation into its precise properties is underway to here fully evaluate its therapeutic benefit .
Mapatumumab (HGS-ETR1): A Targeted Therapy for Idiopathic Pulmonary Fibrosis
Mapatumumab (HGS-ETR1) represents the promising focused therapy strategy for addressing usual lung fibrosis . This protein specifically inhibits its function , an receptor involved in cell formation and pathological protein synthesis. Initial patient results suggest therapeutic effect in reducing disease , while ongoing research are required to definitively assess its effectiveness and safety .